Erasca Inc. Common Stock vs F5 Inc — how do they compare? Erasca Inc. Common Stock trades at $15.57 (market cap $4.95B), while F5 Inc trades at $460.99 (market cap $26.42B). The key difference: F5 Inc is far larger — about 5.3× Erasca Inc. Common Stock's market cap, and F5 Inc is trading nearer its 52-week high, Erasca Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 0 Days and F5 Inc for 38 Days on average.
| ERAS | FFIV | |
|---|---|---|
Market Cap | $4.95B | $26.42B |
Volume | 3,834,689 | 454,868 |
Sector | Health | Technology |
52-Week High | $22.47 | $469.79 |
52-Week Low | $2.20 | $223.99 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $4.72B | $25.06B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
F5 (FFIV) trades at $466.65, down 0.67% on the day, as the stock consolidates near recent highs following strong year-to-date performance. The company continues to demonstrate robust fundamentals with revenue growth accelerating to $3.09 billion in 2025 and net income reaching $692 million, representing a 22.4% margin. Recent analyst recognition as a leader in WAAP platforms and AI security positions F5 well in the growing cybersecurity market. Technical indicators show the stock trading near resistance at $468 with bullish moving averages but overbought RSI readings suggesting potential near-term consolidation.
F5 presents a compelling growth story with consistent earnings beats and expanding profitability, though current valuation multiples appear elevated. The main investment opportunity lies in the company's leadership in application security and AI-driven solutions, while risks include competitive pressures and execution challenges in maintaining growth momentum. Analyst consensus remains cautiously optimistic with a $416.60 price target, indicating potential downside from current levels despite the positive business trajectory.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →